Thursday, 21 September 2017

Asia Pacific Bleeding Disorders Treatment Market Competitive landscape analysis

Asia Pacific Bleeding Disorders Treatment Market was worth USD 2.07 billion in 2016 and is estimated to be growing at a CAGR of 8.90%, to reach USD 3.16 billion by 2021.


The market is showcasing evident potential in the mentioned forecasting period. A bleeding disorder is a condition which affects the clotting (coagulation) system of the body. If not taken care of this condition properly, serious damage can happen to body in case of any wound or cut due to excessive loss of blood from the body.


There are various types of Bleeding Disorders, but the most frequently seen cases are of Hemophilia A, Hemophilia B and von Willebrand Disease  (vWD). A bleeding Disorder is generally diagnosed by any of these three methods: Platelet Aggregation Test, Complete Blood Count (CBC) and bleeding time. There are various treatment methods depending on the type of bleeding disorder and its severity. Treatments include Iron Supplementation pills, Blood transfusion and other methods.


Because of careless unbalanced diet of teenagers now-a-days in this region, iron deficiency in their body can take place easily, which is the root cause for bleeding disorders. Increasing cases of adulteration of food in this region is one of the reason of many people suffering from bleeding disorders and indirectly supporting this market. Also, the fact that most of the bleeding disorders are inherited and cannot be completely cured is also driving this market. On the other hand, factors such as, high cost of treatment including medication and lack of skilled practitioners to cure these type of disorders are challenging this market.


The Asia-Pacific market for Bleeding Disorders Treatment is broadly categorized by Drug Class and by Disorder Type. On the basis of Drug Class, it is further sub-categorized into Fibrin Sealant, Desmopressin, Antibrinolytics, Recombinant Coagulation Factor Concentrates and Plasma Derived Coagulation Factor Concentrates. On the basis of disorder type, it is sub-categorized into Hemophilia A, Hemophilia B ad vWD. The recombinant coagulation factor concentrates segment is expected to grow the fastest in the mentioned forecast period. This is because of the increased R&D in this market and increasing focus of pharmaceutical companies on recombinant products.

Geographically, Asia-Pacific market is further sub-categorized into India, China, Japan, South Korea and Australia. Asia-Pacific Region has the highest growth rate among all the geographical segments. China leads the market in this region in terms of market share while India has the highest growth rate in this region.

Some of the major companies dominating the market, by their products and services include CSL Behring, Pfizer Inc., Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Janssen Asia-Pacific Services, LLC and Grifos SA.

About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.

Contact:
Abhishek Shukla                                       
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/  
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases           


No comments:

Post a Comment